ArticleMedicine2026
Effect of genetically proxied plasma sclerostin levels on the risk of ischemic stroke: A drug-target Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence of a causal link between sclerostin-lowering interventions and ischemic stroke remains uncertain due to the limitations of previous observational studies and the post hoc analyses of randomized trials. Therefore, this study aims to investigate the causal effect of plasma sclerostin abundance on incident ischemic stroke and its subtypes. To do this, we conducted a drug-target Mendelian randomization analysis. First, we established a primary hypothesis holding that genetically perturbed plasma sclerostin levels are causally associated with any ischemic stroke (AIS). We then established exploratory hypotheses to test whether plasma sclerostin levels could affect the risk of subtypes of several types of ischemic stroke, in this case cardiometabolic stroke, large artery stroke (LAS), and small vessel stroke. For phenotypes that showed a statistically significant effect, we conducted Bayesian colocalization analyses to test for confounding by linkage disequilibrium. As a result, we identified a single cis-acting genetic instrument perturbing plasma sclerostin levels. A significant effect of reduced sclerostin levels on increased odds for AIS was observed (odds ratio per 1-unit decrease in sclerostin levels: 1.32; 95% confidence interval: 1.03-1.68; P = .027). Additionally, among the 3 subtypes of ischemic stroke, the odds for LAS were significantly affected by sclerostin levels under a Bonferroni-adjusted significance level (odds ratio: 2.71; 95% confidence interval: 1.31-5.61; P = .007). No statistical evidence of confounding by linkage disequilibrium was observed with AIS (PP.H3 = 4.13 × 10-3) or LAS (PP.H3 = .0104). In conclusion, reduced plasma sclerostin levels could increase the risk of ischemic stroke, particularly LAS, suggesting the importance of monitoring cerebrovascular risk in patients receiving sclerostin-reducing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.